about
Alprazolam for essential tremorAlprazolam for essential tremorZonisamide for essential tremorTopiramate for essential tremorPregabalin for essential tremorSecond consensus statement on the diagnosis of multiple system atrophyDihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonistsThe dopaminergic response in multiple system atrophy.EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson's disease.Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm.Accuracy of clinical diagnosis of progressive supranuclear palsy.Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients.Systematic review of severity scales and screening instruments for tics: Critique and recommendationsIxcellence Network®: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection.Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease.Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.A comparative study of primary and secondary hemifacial spasm.Lewy body cortical involvement may not always predict dementia in Parkinson's disease.Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.The European Multiple System Atrophy-Study Group (EMSA-SG).Head trauma in primary cranial dystonias: a multicentre case-control study.Management of multiple system atrophy: state of the art.Drug Insight: new drugs in development for Parkinson's disease.The natural history of multiple system atrophy: a prospective European cohort studyClinical value of botulinum toxin in neurological indications.Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment.Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia.Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations.Craniocervical dystonia: clinical and pathophysiological features.Diagnostic criteria for multiple system atrophy and progressive supranuclear palsy.The potential prognostic role of cardiovascular autonomic failure in α-synucleinopathies.Fifty years of progressive supranuclear palsy.The role of subcutaneous infusion of apomorphine in Parkinson's disease.Scales for hyperkinetic disorders: A systematic review.Zonisamide for essential tremor.The rise and fall of impulse control behavior disorders.Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms.
P50
Q24187196-4393A1B9-6788-4D84-B17E-E5DE46C54B4DQ24201430-E3412EF1-F8BB-4D48-89F9-B394D5D786AEQ24201497-8ECC4232-8AC9-4E42-9ACF-DE2FE5F6C528Q24201606-21EE0841-D585-40DC-BC7C-BD4FC727CC40Q24203614-1572E669-9AF2-459E-B497-4E4042A5855FQ24650965-77E951B6-EDBE-42AB-91FA-38857ABDBFEDQ28201003-91B46094-92C2-40F3-AFFC-070E61971904Q28317869-6FAFADFA-250B-4543-9801-5F6C87E718DDQ30583771-09B29034-6298-48F5-A612-0E84C2104207Q31143768-46441D04-E411-45D4-AA0F-0028B6781B2DQ33198540-3DE40168-73DC-48A6-8BF3-8F6FBB25790EQ33735320-2D442C70-8057-46C2-B2DB-A03528CA099CQ33735394-98DA517A-6FCA-4BDF-84D0-1B5515DDD83FQ33828618-1DB43567-47DC-48A8-BEEB-A4A544831F0AQ33897459-51FF04F8-78B2-4A49-82F6-181FBCB81A07Q34351580-2E1FEE46-2127-4BF8-AE42-AED234D4C2F5Q34376919-D3A1841C-6D00-4B52-BA49-0419F0555186Q34501739-1A36B0D8-B87B-4598-A3EE-D5CFA8F427C6Q35474472-B2507E36-F975-4C76-B897-5785CACE78AFQ35969183-7B726990-26B3-4CC2-874F-79B78B34CFC0Q36210318-46A9BEFB-A998-487F-9CE5-26A7F6818722Q36226868-0A6FCB6F-542C-4ACD-8924-9C84B9ED427BQ36311957-2A13BDD7-5707-43CC-AC05-6044696F074EQ36631654-8B623CCD-D11F-4A85-9C3E-3F99F62C6CBFQ36637012-BA652705-EA9D-4688-AB1D-48AD70CDF3C5Q36656469-0FCDFE60-A2D5-474F-83F6-24EDEB551755Q37385804-584C527E-EDCA-4B32-964E-A3C60BF26947Q37388338-1FA632C9-E659-4E43-8CB4-A6B354FE178AQ37716740-BE490245-541C-45C9-8A26-2722C18CE08EQ37768836-81522C76-9E57-4E4C-91C6-0D115DF74045Q37784910-8525D703-23C5-4F30-B0C6-50AB0A73239FQ38029778-775E5207-7A40-4A59-B4CE-5A478917CC4AQ38135221-542B879C-A3EF-431D-915A-B0C0D963BE1EQ38219351-4C162AC4-FB62-4F47-AA63-8A8E23636301Q38597216-C11AA786-93AC-4A15-BEE3-6AECED98DEE0Q38610647-6B64837B-292D-4AD0-AE2E-2DB7EB8F042DQ38640772-00DE1372-E22E-48CC-B76C-682BF1D23FF0Q38807324-1FE04226-50EE-4120-B186-B01209B2C7EDQ39303669-26BFFBAC-8022-432B-8DD2-FA56EEC4D216Q39552636-F0EFDF5F-F473-4144-94E8-03B5BE2D2CDB
P50
description
onderzoeker
@nl
name
Carlo Colosimo
@ast
Carlo Colosimo
@en
Carlo Colosimo
@es
Carlo Colosimo
@nl
type
label
Carlo Colosimo
@ast
Carlo Colosimo
@en
Carlo Colosimo
@es
Carlo Colosimo
@nl
prefLabel
Carlo Colosimo
@ast
Carlo Colosimo
@en
Carlo Colosimo
@es
Carlo Colosimo
@nl